{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:13:45Z","timestamp":1779452025208,"version":"3.53.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.rpth.2026.103398","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:11:13Z","timestamp":1771315873000},"page":"103398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9313-5437","authenticated-orcid":false,"given":"Anwar","family":"Almajdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103398_bib1","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2026.103398_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.rpth.2026.103398_bib3","first-page":"448","article-title":"Chronic kidney disease and atrial fibrillation: a contemporary overview","volume":"5","author":"Kulkarni","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.rpth.2026.103398_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf027","article-title":"Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046-a systematic analysis of the Global Burden of Disease Study 2021","volume":"27","author":"Tan","year":"2025","journal-title":"Europace"},{"key":"10.1016\/j.rpth.2026.103398_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.31083\/j.rcm2504143","article-title":"Atrial fibrillation and chronic kidney disease: aetiology and management","volume":"25","author":"Sidhu","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.rpth.2026.103398_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ki.2014.195","article-title":"Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease","volume":"87","author":"Reinecke","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2026.103398_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103398_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.103398_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","article-title":"Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis","volume":"113","author":"Parasrampuria","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103398_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40256-024-00664-2","article-title":"Apixaban use in patients with kidney impairment: a review of pharmacokinetic, interventional, and observational study data","volume":"24","author":"Mandt","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.rpth.2026.103398_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.rpth.2026.103398_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.rpth.2026.103398_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103398_bib14","author":"Sterne"},{"key":"10.1016\/j.rpth.2026.103398_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2026.103398_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2026.103398_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100675","article-title":"Safety and effectiveness of rivaroxaban versus warfarin across GFR levels in atrial fibrillation: a population-based study in Australia and Canada","volume":"5","author":"Ha","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.rpth.2026.103398_bib18","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Cheng","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.103398_bib19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2026.103398_bib20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2026.103398_bib21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2026.103398_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.annepidem.2012.12.011","article-title":"Atrial fibrillation and risk of stroke in dialysis patients","volume":"23","author":"Wetmore","year":"2013","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.rpth.2026.103398_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2026.103398_bib24","first-page":"1125","article-title":"Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4-5 chronic kidney disease or on dialysis: a systematic review and meta-analysis","volume":"36","author":"Chen","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.rpth.2026.103398_bib25","series-title":"Xarelto (rivaroxaban) summary of product characteristics","year":"2020"},{"key":"10.1016\/j.rpth.2026.103398_bib26","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.103398_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.103398_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.ajkd.2010.02.348","article-title":"Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study","volume":"56","author":"Muntner","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2026.103398_bib29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2005010005","article-title":"Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study","volume":"16","author":"Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2026.103398_bib30","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2026.103398_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103398_bib32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/03007995.2016.1237937","article-title":"Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study","volume":"32","author":"Coleman","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rpth.2026.103398_bib33","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.103398_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"key":"10.1016\/j.rpth.2026.103398_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rpth.2026.103398_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2215\/CJN.01810407","article-title":"Major bleeding in hemodialysis patients","volume":"3","author":"Holden","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2026.103398_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000445329","article-title":"Rivaroxaban in chronic hemodialysis patients","volume":"43","author":"Muster","year":"2016","journal-title":"Am J Nephrol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:01:10Z","timestamp":1779451270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2475037926000567"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103398","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103398"}}